STAGING ENVIRONMENT - Not for production use
Skip to main content

[PLACEHOLDER CONTENT]

Clinical Regulatory Services

Clinical Regulatory Strategy for Rare Disease and Advanced Therapy Programs

RareMoon provides expert clinical regulatory strategy tailored to the unique challenges of rare disease drug development. Our team partners with sponsors to design and execute clinical development programs that meet regulatory expectations while addressing the complexities inherent in small patient populations and novel therapeutic modalities.

From first-in-human studies through pivotal trials and marketing applications, we guide sponsors through clinical regulatory milestones across FDA, EMA, and global health agencies. Our deep experience with gene therapies, cell therapies, and orphan drugs ensures that clinical strategies are aligned with the latest regulatory thinking on endpoints, study design, and evidentiary standards for rare diseases.

Clinical development strategy and regulatory pathway planning
Protocol design and regulatory review support
Clinical study report and submission authoring
Pediatric investigation plan (PIP) and pediatric study plan (PSP) strategy
Clinical contributions to regulatory briefing documents
Endpoint strategy and natural history study guidance

Partner with RareMoon for Clinical Strategy

Contact us to discuss how our clinical regulatory expertise can accelerate your rare disease program through development milestones.